Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mevrometostat in Relapsed/Refractory SCLC, CRPC, and FL
NCT03460977Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2018
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of mevrometostat in small cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC) and follicular lymphoma (FL) (2 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 90 days, Adverse Events at 2 years and 4 more. Started Apr 2018; status: recruiting.
02
Drugs
mevrometostat
03
Conditions
small cell lung cancer (SCLC)castration-resistant prostate cancer (CRPC)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03460977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03460977.